Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absorption
The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Thiazolidinediones (TZDs) are widely used to treat type 2 diabetes mellitus; however, their use is complicated by systemic fluid retention. Along the nephron, the pharmacological target of TZDs, peroxisome proliferator-activated receptor-gamma (PPARgamma, encoded by Pparg), is most abundant in the collecting duct. Here we show that mice treated with TZDs experience early weight gain from increased total body water. Weight gain was blocked by the collecting duct-specific diuretic amiloride and was also prevented by deletion of Pparg from the collecting duct, using Pparg (flox/flox) mice. Deletion of collecting duct Pparg decreased renal Na(+) avidity and increased plasma aldosterone. Treating cultured collecting ducts with TZDs increased amiloride-sensitive Na(+) absorption and Scnn1g mRNA (encoding the epithelial Na(+) channel ENaCgamma) expression through a PPARgamma-dependent pathway. These studies identify Scnn1g as a PPARgamma target gene in the collecting duct. Activation of this pathway mediates fluid retention associated with TZDs, and suggests amiloride might provide a specific therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Weight gain with PPAR-γ agonists, such as pioglitazone, reflects an increase in adipose tissue mass and a tendency for fluid accumulation owing to renal sodium retention.41”
From Pioglitazone after Ischemic Stroke or Transient Ischemic Attack (2016) · cites this paper as [41]
Citations
Cites
Generalized lacZ expression with the ROSA26 Cre reporter strain
Soriano, P. (1999) · Nature Genetics · doi:10.1038/5007 · Cited by 4,859
Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-γ
Picard, F., Kurtev, M., Chung, N., Topark-Ngarm, A., Senawong, T., Machado de Oliveira, R., Leid, M., McBurney, M. W., & Guarente, L. (2004) · Nature · doi:10.1038/nature02583 · Cited by 1,952
Yki-Järvinen, H. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041001 · Cited by 1,830
Epithelial sodium channels: function, structure, and regulation
Garty, H., & Palmer, L. G. (1997) · Physiological Reviews · doi:10.1152/physrev.1997.77.2.359 · Cited by 1,155
Case Report and Literature Review
Spoden, J. E., Bumsted, R. M., & Warner, E. D. (1980) · Annals of Otology, Rhinology & Laryngology · doi:10.1177/000348948008900320 · Cited by 1,094
Nesto, R. W., Bell, D., Bonow, R. O., Fonseca, V., Grundy, S. M., Horton, E. S., Le Winter, M., Porte, D., Semenkovich, C. F., Smith, S., et al. (2003) · Circulation · doi:10.1161/01.cir.0000103683.99399.7e · Cited by 829
Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure
Nesto, R. W., Bell, D., Bonow, R. O., Fonseca, V., Grundy, S. M., Horton, E. S., Le Winter, M., Porte, D., Semenkovich, C. F., Smith, S., et al. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.256 · Cited by 585
Transcriptional Repression of Atherogenic Inflammation: Modulation by PPARδ
Lee, C.-H., Chawla, A., Urbiztondo, N., Liao, D., Boisvert, W. A., & Evans, R. M. (2003) · Science · doi:10.1126/science.1087344 · Cited by 580
Leesnitzer, L. M., Parks, D. J., Bledsoe, R. K., Cobb, J. E., Collins, J. L., Consler, T. G., Davis, R. G., Hull-Ryde, E. A., Lenhard, J. M., Patel, L., et al. (2002) · Biochemistry · doi:10.1021/bi0159581 · Cited by 566
Whitehead, R. H., VanEeden, P. E., Noble, M. D., Ataliotis, P., & Jat, P. S. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.2.587 · Cited by 364
Cited by
Mechanisms of fatty acid-induced inhibition of glucose uptake.
Boden, G., Chen, X., Ruiz, J., White, J. V., & Rossetti, L. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117252 · Cited by 3,705
PPARγ signaling and metabolism: the good, the bad and the future
Ahmadian, M., Suh, J. M., Hah, N., Liddle, C., Atkins, A. R., Downes, M., & Evans, R. M. (2013) · Nature Medicine · doi:10.1038/nm.3159 · Cited by 2,016
Lehrke, M., & Lazar, M. A. (2005) · Cell · doi:10.1016/j.cell.2005.11.026 · Cited by 1,443
Low Wang, C. C., Hess, C. N., Hiatt, W. R., & Goldfine, A. B. (2016) · Circulation · doi:10.1161/circulationaha.116.022194 · Cited by 1,155
Pioglitazone after Ischemic Stroke or Transient Ischemic Attack
Kernan, W. N., Viscoli, C. M., Furie, K. L., Young, L. H., Inzucchi, S. E., Gorman, M., Guarino, P. D., Lovejoy, A. M., Peduzzi, P. N., Conwit, R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1506930 · Cited by 1,124
PPAR and human metabolic disease
Semple, R. K. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28003 · Cited by 827
PPARs in Obesity-Induced T2DM, Dyslipidaemia and NAFLD
Gross, B., Pawlak, M., Lefebvre, P., & Staels, B. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.135 · Cited by 778
Kenny, H. C., & Abel, E. D. (2019) · Circulation Research · doi:10.1161/circresaha.118.311371 · Cited by 660
Dunlay, S. M., Givertz, M. M., Aguilar, D., Allen, L. A., Chan, M., Desai, A. S., Deswal, A., Dickson, V. V., Kosiborod, M. N., Lekavich, C. L., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000691 · Cited by 639
Update on the treatment of type 2 diabetes mellitus
Marín-Peñalver, J. J., Martín-Timón, I., Sevillano-Collantes, C., & Cañizo-Gómez, F. J. D. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i17.354 · Cited by 647
THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Ion channels
Alexander, S. P. H., Mathie, A., Peters, J. A., Veale, E. L., Striessnig, J., Kelly, E., Armstrong, J. F., Faccenda, E., Harding, S. D., Pawson, A. J., et al. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14749 · Cited by 606
Dutchak, P. A., Katafuchi, T., Bookout, A. L., Choi, J. H., Yu, R. T., Mangelsdorf, D. J., & Kliewer, S. A. (2012) · Cell · doi:10.1016/j.cell.2011.11.062 · Cited by 537
Bozkurt, B., Aguilar, D., Deswal, A., Dunbar, S. B., Francis, G. S., Horwich, T., Jessup, M., Kosiborod, M., Pritchett, A. M., Ramasubbu, K., et al. (2016) · Circulation · doi:10.1161/cir.0000000000000450 · Cited by 522
Metabolic Mechanisms in Heart Failure
Ashrafian, H., Frenneaux, M. P., & Opie, L. H. (2007) · Circulation · doi:10.1161/circulationaha.107.702795 · Cited by 521
Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes
Soccio, R. E., Chen, E. R., & Lazar, M. A. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.08.005 · Cited by 518
A multi-layer microfluidic device for efficient culture and analysis of renal tubular cells
Jang, K.-J., & Suh, K.-Y. (2010) · Lab Chip · doi:10.1039/b907515a · Cited by 497
Insulin resistance and atherosclerosis
Semenkovich, C. F. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29024 · Cited by 481
Thiazolidinediones and PPARγ agonists: time for a reassessment
Cariou, B., Charbonnel, B., & Staels, B. (2012) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2012.03.001 · Cited by 390
Omiecinski, C. J., Vanden Heuvel, J. P., Perdew, G. H., & Peters, J. M. (2011) · Toxicological Sciences · doi:10.1093/toxsci/kfq338 · Cited by 369
Falcão-Pires, I., & Leite-Moreira, A. F. (2012) · Heart Failure Reviews · doi:10.1007/s10741-011-9257-z · Cited by 363
Insulin-Resistant Cardiomyopathy
Witteles, R. M., & Fowler, M. B. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.10.021 · Cited by 351
Cardiac cachexia: A systematic overview
von Haehling, S., Lainscak, M., Springer, J., & Anker, S. D. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.09.009 · Cited by 348
Peroxisome Proliferator–Activated Receptors as Transcriptional Nodal Points and Therapeutic Targets
Brown, J. D., & Plutzky, J. (2007) · Circulation · doi:10.1161/circulationaha.104.475673 · Cited by 340
Cardiomyocyte expression of PPARγ leads to cardiac dysfunction in mice
Son, N.-H., Park, T.-S., Yamashita, H., Yokoyama, M., Huggins, L. A., Okajima, K., Homma, S., Szabolcs, M. J., Huang, L.-S., & Goldberg, I. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30335 · Cited by 335
Safety issues and prospects for future generations of PPAR modulators
RUBENSTRUNK, A., HANF, R., HUM, D., FRUCHART, J., & STAELS, B. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.02.003 · Cited by 309
Collecting Duct Principal Cell Transport Processes and Their Regulation
Pearce, D., Soundararajan, R., Trimpert, C., Kashlan, O. B., Deen, P. M. T., & Kohan, D. E. (2015) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.05760513 · Cited by 303
Self-citationNutrition, metabolism, and the complex pathophysiology of cachexia in chronic heart failure
VONHAEHLING, S., DOEHNER, W., & ANKER, S. (2007) · Cardiovascular Research · doi:10.1016/j.cardiores.2006.08.018 · Cited by 300
Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy
Gilbert, R. E., & Krum, H. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61402-1 · Cited by 293
Nuclear Receptors and Their Selective Pharmacologic Modulators
Burris, T. P., Solt, L. A., Wang, Y., Crumbley, C., Banerjee, S., Griffett, K., Lundasen, T., Hughes, T., & Kojetin, D. J. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.006833 · Cited by 283
Kong, W.-J., Zhang, H., Song, D.-Q., Xue, R., Zhao, W., Wei, J., Wang, Y.-M., Shan, N., Zhou, Z.-X., Yang, P., et al. (2009) · Metabolism · doi:10.1016/j.metabol.2008.08.013 · Cited by 267
Peroxisome Proliferator-Activated Receptor-γ–Mediated Effects in the Vasculature
Duan, S. Z., Usher, M. G., & Mortensen, R. M. (2008) · Circulation Research · doi:10.1161/circresaha.107.164384 · Cited by 263
The Toxicology of Ligands for Peroxisome Proliferator-Activated Receptors (PPAR)
Peraza, M. A., Burdick, A. D., Marin, H. E., Gonzalez, F. J., & Peters, J. M. (2006) · Toxicological Sciences · doi:10.1093/toxsci/kfj062 · Cited by 254
Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial
Komajda, M., McMurray, J. J. V., Beck-Nielsen, H., Gomis, R., Hanefeld, M., Pocock, S. J., Curtis, P. S., Jones, N. P., & Home, P. D. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehp604 · Cited by 234
Pioglitazone: the forgotten, cost-effective cardioprotective drug for type 2 diabetes
DeFronzo, R. A., Inzucchi, S., Abdul-Ghani, M., & Nissen, S. E. (2019) · Diabetes and Vascular Disease Research · doi:10.1177/1479164118825376 · Cited by 223
PPARs and lipid ligands in inflammation and metabolism
Harmon, G. S., Lam, M. T., & Glass, C. K. (2011) · Chemical Reviews · doi:10.1021/cr2001355 · Cited by 216
Kung, J., & Henry, R. R. (2012) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2012.691963 · Cited by 198
Covalent Peroxisome Proliferator-activated Receptor γ Adduction by Nitro-fatty Acids
Schopfer, F. J., Cole, M. P., Groeger, A. L., Chen, C.-S., Khoo, N. K. H., Woodcock, S. R., Golin-Bisello, F., Motanya, U. N., Li, Y., Zhang, J., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.091512 · Cited by 171
How safe is the use of thiazolidinediones in clinical practice?
Rizos, C., Elisaf, M., Mikhailidis, D., & Liberopoulos, E. (2009) · Expert Opinion on Drug Safety · doi:10.1517/14740330802597821 · Cited by 161
Dunlay, S. M., Givertz, M. M., Aguilar, D., Allen, L. A., Chan, M., Desai, A. S., Deswal, A., Dickson, V. V., Kosiborod, M. N., Lekavich, C. L., et al. (2019) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2019.05.007 · Cited by 145
Glucocorticoid-induced diabetes mellitus: prevalence and risk factors in primary renal diseases
Uzu, T., Harada, T., Sakaguchi, M., Kanasaki, M., Isshiki, K., Araki, S., Sugiomoto, T., Koya, D., Haneda, M., Kashiwagi, A., et al. (2006) · Nephron Clinical Practice · doi:10.1159/000097598 · Cited by 136
Pioglitazone Improves Left Ventricular Diastolic Function in Subjects With Diabetes
Clarke, G. D., Solis-Herrera, C., Molina-Wilkins, M., Martinez, S., Merovci, A., Cersosimo, E., Chilton, R. J., Iozzo, P., Gastaldelli, A., Abdul-Ghani, M., et al. (2017) · Diabetes Care · doi:10.2337/dc17-0078 · Cited by 63
Chen, Z., Yuan, P., Sun, X., Tang, K., Liu, H., Han, S., Ye, T., Liu, X., Yang, X., Zeng, J., et al. (2019) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00047.2019 · Cited by 46
BERRIA, R., GASTALDELLI, A., LUCIDI, S., BELFORT, R., DEFILIPPIS, E., EASTON, C., BRYTZKI, R., CUSI, K., JOVANOVIC, L., & DEFRONZO, R. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.03.014 · Cited by 33
McGuire, D. K., Abdullah, S. M., See, R., Snell, P. G., McGavock, J., Szczepaniak, L. S., Ayers, C. R., Drazner, M. H., Khera, A., & de Lemos, J. A. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq228 · Cited by 29
PANCHAPAKESAN, U., POLLOCK, C., & SAAD, S. (2009) · Nephrology · doi:10.1111/j.1440-1797.2009.01089.x · Cited by 25
Perelman, D., Coghlan, N., Lamendola, C., Carter, S., Abbasi, F., & McLaughlin, T. (2017) · Gynecological Endocrinology · doi:10.1080/09513590.2016.1259407 · Cited by 18
Metadata
- Authors
- Guan, Y., Hao, C., Cha, D. R., Rao, R., Lu, W., Kohan, D. E., Magnuson, M. A., Redha, R., Zhang, Y., & Breyer, M. D.
- Affiliations
- Vanderbilt University (US)
- United States Department of Veterans Affairs (US)
- Corresponding author
- Breyer, Matthew D
- Venue
- Nature Medicine
- Published
- 2005-07-10
- Volume
- 11
- Issue
- 8
- Pages
- 861-866
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2082432305
- Cited by
- 608
- References
- 42
- Citations by year
- 2026: 10 · 2025: 16 · 2024: 6 · 2023: 15 · 2022: 11 · 2021: 19 · 2020: 14 · 2019: 22 · 2018: 16 · 2017: 23 · 2016: 28 · 2015: 25 · 2014: 31 · 2013: 36 · 2012: 33
- FWCI
- 20.45
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01dk065074-05)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK37097, DK 38226, DK59637, R01DK037097, R01 DK65074-01, P01DK038226)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ion Transport and Channel Regulation
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Keywords
- thiazolidinediones, PPARγ, epithelial sodium channel, collecting duct, fluid retention, body fluid volume, SCNN1G, amiloride, aldosterone, type 2 diabetes, weight gain, PPARγ target genes
- MeSH terms
- Amiloride, Analysis of Variance, Animals, Blood Chemical Analysis, Body Fluids, Body Weight, Diabetes Mellitus, Type 2, Mice, Transgenic, Nephrons, Sodium, Water-Electrolyte Balance, Sodium Channels, Gene Targeting, Reverse Transcriptase Polymerase Chain Reaction, Thiazolidinediones, Chromatin Immunoprecipitation, PPAR gamma, Mice, Epithelial Sodium Channels
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.